VaxInnate licensed to use 3M Drug Delivery Systems' TLR agonists

3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M’s patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M’s TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.

Under the terms of the non-exclusive licensing agreement, 3M provides its TLR agonists to VaxInnate for an undisclosed licensing fee, in addition to milestone and royalty payments.

“Pairing our TLR agonists with VaxInnate’s innovative vaccine technology has the potential for increasing the effectiveness of vaccines,” said Dr. Mark Tomai, PhD, Vaccine Business Development Director, 3M Drug Delivery Systems.

“The combination of VaxInnate’s proprietary vaccine technology with 3M’s TLR agonists could improve vaccine potency and make a major contribution to global public health,” said Alan Shaw PhD, VaxInnate CEO. “We look forward to this collaboration with 3M.”